
FDA Approves AAVantgarde’s IND Application for Stargardt Gene Therapy
AAVantgarde Bio, a clinical-stage, biotechnology company specializing in inherited retinal diseases, announced on July 15, 2025, that FDA has cleared the company’s investigational new drug application for AAVB-039, a gene therapy to treat Stargardt disease …